A Phase 1/2 interventional study of SKG0106 in Neovascular Age-related Macular Degeneration, sponsored by Skyline Therapeutics (US) Inc.. Recruiting at 9 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Skyline Therapeutics (US) Inc. (part of Xiamen Amoytop Biotech Co., Ltd.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.
Among the 107 studies in Macular Degeneration with a site in China, this one is the 42nd largest by planned enrollment of the 91 interventional ones that give a count, is one of 7 that started in 2024, is one of 18 in phase 1/2, reaches primary completion later than 25 of the 42 other live ones, and was the 69th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 50–85
Novartis Pharmaceuticals · Sites in China, United States, Argentina and 16 more countries
Ages 50+
Innostellar Biotherapeutics Co.,Ltd · Sites in China
Ages 50–80
Innovent Biologics Technology Limited (Shanghai R&D Center) · Sites in China
Ages 50+
Peking University People's Hospital · Sites in China
Ages 50+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 36 · Phase 3 22 · Phase 4 5
First in 2008; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 68 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 62 across the 91 interventional studies, 300 across the 16 observational. Of the 40 that completed or were terminated, 6 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 107 have an industry lead sponsor. The 10 most frequent:
This study is registered under Skyline Therapeutics (US) Inc., one of the names counted as Xiamen Amoytop Biotech Co., Ltd.. Under that name alone:
This is the only study on the registry with Skyline Therapeutics (US) Inc. as lead sponsor.
Xiamen Amoytop Biotech Co., Ltd. has 2 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
11 of the studies in Macular Degeneration with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05972473Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD | 2027-02-28 |
| NCT07189169Phase 3Smilebiotek Zhuhai LimitedQA108 Phase III Study in Subjects With Intermediate AMD | 2027-03-01 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT07053358Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSafety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients | 2026-11-23 |
| NCT07409389The Hong Kong Polytechnic UniversityRepeated Low-Level Red-Light Therapy in Dry Age-Related Macular Degeneration | 2026-12-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 107 studies in Macular Degeneration with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Aged ≥ 50 years at screening;
Study Eye:
Exclusion Criteria:
SKG0106 One-Time Intraocular Injection Dose Level 1
Genetic: SKG0106
SKG0106 One-Time Intraocular Injection Dose Level 2
Genetic: SKG0106
SKG0106 One-Time Intraocular Injection Dose Level 3
Genetic: SKG0106
SKG0106 is a recombinant adeno-associated virus (AAV) vector-based in vivo gene therapeutic product
Characteristics of dose limiting toxicities (DLTs)
Time frame: 4 Weeks
Type, severity, and incidence of ocular and systemic adverse events (AEs)
Time frame: 52 Weeks
Mean change from baseline in best corrected visual acuity (BCVA) at each visit
BCVA of the study eye is examined by the Early Treatment of Diabetic Retinopathy Study (ETDRS) testing at screening and baseline.
Time frame: 52 Weeks
Mean change from baseline in central subfield thickness (CST) at each visit
Spectral domain optical coherence tomography (SD-OCT) will be performed to measure CST at screening and at each visit (prior to study drug injection, if available).
Time frame: 52 Weeks
Mean change from baseline in patient-reported outcome (VFQ-25) scale score at each visit
Both the total scale and subscale scores of the VFQ-25 is ranging from 0 to 100, and higher scores mean a better outcome.
Time frame: 52 Weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Jan 2027, 35 months after the start.
Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 35 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.